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ABSTRACT
Luteinizing hormone (LH) is a key regulator of male fertility
through its effects on testosterone secretion by Leydig cells.
Transcriptional control of this is, however, currently poorly
understood. Mice in which the LH receptor is knocked out
(LuRKO) show reduced testicular size, reduced testosterone,
elevated serum LH, and a spermatogenic arrest that can be
rescued by the administration of testosterone. Using genome-
wide transcription profiling of LuRKO and control testes during
postnatal development and following testosterone treatment, we
show that the transcriptional effects of LH insensitivity are
biphasic, with an early testosterone-independent phase and a
subsequent testosterone-dependent phase. Testosterone rescue
reenables the second, testosterone-dependent phase of the
normal prepubertal transcription program and permits the
continuation of spermatogenesis. Examination of the earliest
responses to testosterone highlights six genes that respond
rapidly in a dose-dependent fashion to the androgen and that are
therefore candidate regulatory genes associated with the
testosterone-driven progression of spermatogenesis. In addition,
our transcriptional data suggest a model for the replacement of
fetal-type Leydig cells by adult-type cells during testicular
development in which a testosterone feedback switch is
necessary for adult Leydig cell production. LH signaling affects
the timing of the switch but is not a strict requirement for Leydig
cell differentiation.
early development, Leydig cells, luteinizing hormone, spermatid,
spermatogenesis, testis, testosterone
INTRODUCTION
Prepubertal growth and development of the testis is
controlled through a balance of genetic and hormonal factors
operating in a microenvironment of somatic and gametic cells,
involving extensive cell-cell interactions and hormonal signal-
ing. Endocrine control of this process is exerted via the
hypothalamo-pituitary-gonadal axis in which gonadotropin-
releasing hormone from the hypothalamus triggers secretion of
follicle-stimulating hormone (FSH) and luteinizing hormone
(LH) from the pituitary. These two hormones in turn support
testis growth and development [1].
Deeper understanding the mode of action of these hormones
can be achieved through the study of animal models in which
the hormones themselves, or their receptors, are absent or
nonfunctional. Such studies indicate that while FSH is
important for the control of Sertoli cell proliferation and overall
testis size, it is not required for fertility because male mice
lacking FSH, or its receptor, are fertile despite reduced testicular
volume [2–4]. In contrast, LH is strictly necessary for male
function. There are two mutant mouse model systems in which
the LH pathway is ablated [5, 6], and both are cryptorchid and
infertile. Of these, the best characterized is the LuRKO (LH
receptor knocked out) model in which exon 11 of the Lhcgr
gene encoding the LH receptor is deleted. This exon encodes
the intracellular and transmembrane domains, and its loss leads
to a total lack of receptor function. The comparison of the
prepubertal testis development of LuRKO mice with normal
controls provides a unique insight into the contribution of LH to
this process. In male LuRKO mice, testicular size is
significantly reduced from around Day 13 postpartum, and
normal germ cell differentiation is disrupted, arresting at the
early round spermatid stage around Days 19–20 postpartum [5].
Evidence from several prior studies suggests that the effects
of LH are largely mediated via the stimulation of testosterone
production by the Leydig cells. Spermatogenesis in the
hypogonadal (hpg) mouse, which lacks both FSH and LH,
can be restored by treatment either with exogenous human
chorionic gonadotropin (hCG), an alternate ligand for the LH
receptor, or with testosterone, although the mice remain
infertile due to impaired sexual behavior [7, 8]. In LuRKO
mice, testosterone treatment restores spermatogenesis and
partially restores fertility, although there is still a reduction in
accessory gland function and impaired sexual behavior [9].
Sertoli cells are a key testosterone target in the developing
postnatal testis, and the SCARKO (Sertoli cell androgen
receptor knockout) mouse model, which has a selective loss of
androgen receptor function in Sertoli cells, shows a similar
phenotype to the LuRKO mouse [10]. Nevertheless, the
presence of androgen receptors on other cell types in the
testis, including peritubular myoid cells [11] and the Leydig
cells themselves [12], indicates that Sertoli cells are not the
only target for testosterone.
Luteinizing hormone levels in normal mice are low
throughout pregnancy and after birth. Luteinizing hormone
levels rise sharply with the onset of puberty between Days 20
and 25 of postnatal life, peaking around Day 30 and then
declining slowly thereafter [13]. Testosterone levels, however,
follow a more complex profile. Androgen support in fetal and
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perinatal life is provided by the fetal-type Leydig cells, which
secrete androgen independently of LH. Testosterone levels rise
throughout pregnancy, peaking around the time of birth, and
then dropping rapidly thereafter [14]. Adult Leydig cells
replace the fetal cells from around Day 7 postpartum and
subsequently proliferate in an LH-dependent manner [15, 16].
Testosterone secretion in adult Leydig cells is LH dependent,
and thus they are believed to remain largely quiescent until the
pubertal LH surge. This then triggers a corresponding rise in
testosterone from around Day 25 postpartum, reaching full
adult levels by about Day 40 postpartum. In LuRKO males,
where Leydig cells are markedly reduced in size and number,
there is no pubertal surge in testosterone, and adult testosterone
levels in the serum are very significantly reduced, indicating
that pubertal androgen activity requires LH stimulation. Serum
LH levels in adult LuRKO males are elevated over tenfold due
to loss of negative feedback regulation by testosterone at the
level of the pituitary [9]. Testicular descent, prostate and
seminal vesicle growth, and maturation of the external genitalia
are all dependent on this pubertal androgen surge and are
abrogated in LuRKO male mice [5].
Given the hormonal profiles outlined above, the spermato-
genic arrest in LuRKO presents an apparent paradox: the onset
of arrest is at or before Day 19 postpartum, when testosterone
levels are their lowest during normal development [17], and yet
the arrest is clearly androgen dependent, as shown by hormone
replacement experiments. A second puzzling feature is that
older LuRKO males show breakthrough spermatogenesis, with
all the germ cell stages being present in the testis at 12 mo of
age despite continuing lack of LH activity, low number of
Leydig cells, and sustained low testosterone levels [18]. The
spermatogenic arrest is thus best characterized as an extreme
delay in progression rather than a complete block.
The molecular mechanisms through which LH achieves its
effects remains largely underexplored, and the transcriptional
effects underlying the promotion of germ cell differentiation by
LH are unknown. Through RT-PCR analysis, O’Shaughnessy
et al. [17] identified five groups of genes based on their
expression in normal fetal and adult Leydig cells, and Zhang et
al. [19] subsequently examined the expression of some of these
genes in prepubertal LuRKO testes. These studies however
addressed only a few selected candidate genes, and a global
overview of the transcriptional changes in LuRKO mice testes
compared to normal controls has yet to be presented.
This study aims to investigate the role of LH and testosterone
during prepubertal testicular development by performing
transcriptional profiling of RNA from LuRKO mice testes at
a range of prepubertal developmental time points compared to
normal controls and at various time points following the
administration of varying doses of testosterone. Because the
delay/arrest seen in LuRKO mice occurs during this first wave,
developmental profiling during the window surrounding the
onset of arrest is a valid strategy for this model; this avoids the
artifacts that can be introduced using an approach based on
enzymatic digestion of the testis and cell separation. We chose a
whole transcriptome approach to produce a global overview of
gene expression changes as well as a detailed exposition of the
individual genes involved, the data of which might be used for
further studies. In particular, we sought:
1. To identify genes deregulated in the testes of LuRKO mice
prior to the replacement of the fetal Leydig cell population
2. To determine whether the fetal Leydig cell androgen
production is LH dependent in vivo and identify potential
non-testosterone-mediated effects of LH
3. To identify gene changes associated with the onset of
spermatogenic arrest in LuRKO mice
4. To determine whether the transcriptional changes were
detectable in advance of the observed histological changes
and whether the genes concerned included known LH/
androgen response genes, which will also help resolve the
issues surrounding the timing of the arrest in LuRKO germ
cell progression
5. To determine which of the changes identified in 3 were
corrected by testosterone replacement
6. To distinguish the upstream regulatory genes from their
downstream targets by following the time course and dose-
dependent responses to testosterone therapy
7. To determine which of the changes identified in 3 could be
induced by low-dose testosterone therapy, which relates to
the reinitiation of spermatogenesis in aging LuRKO males
with constitutively low testosterone
In so doing, we have highlighted candidate regulatory genes
responsible for the action of LH and testosterone that may well
be applicable to human fertility.
MATERIALS AND METHODS
LuRKO Testis Samples
LuRKO (official allele symhol Lhcgrtm1Hht) mice were maintained at the
University of Oxford Department of Human Anatomy and Genetics, and all
procedures were carried out in accordance with the Animals (Scientific
Procedures) Act 1986 and with the approval of the Local Research and Ethics
Committee. Testes were collected by dissection following cervical dislocation
of the animal. Whole testes were snap frozen in liquid nitrogen and stored at
808C prior to RNA extraction.
Experimental Design
Three experimental series were obtained. Series (a): a developmental time
course examining LuRKO and wild-type littermate testes at Days 3, 8, 13, 19,
and 27 postpartum, taking birth as Day 1. Series (b): a rescue time course
following the testicular response to testosterone propionate treatment (2.5 mg)
at 2, 4, 8, 12, 24, and 48 h postinjection. Series (c): a second rescue time course
to examine the dose sensitivity of the androgen response at 24 h using varying
doses of testosterone propionate (vehicle-only control, 250 ng, 2.5 lg, 25 lg,
and 2.5 mg). Supplemental Data S1 (this and all supplemental data are available
online at www.biolreprod.org) is a schematic showing the relationship between
the three experimental series. For the two rescue series, Day 19 LuRKO males
were given a single subcutaneous injection of the appropriate dose of
testosterone propionate in 0.1 ml arachis oil. The controls for the two rescue
series were the Day 19 sample from the developmental time course
(constituting a time zero untreated sample) and a vehicle-only control harvested
at 24 h postinjection. The 2.5 mg/24 h sample appears in both rescue series, as
the penultimate time point of series (b) and the high-dose endpoint of series (c).
Supplemental Data S2 shows the serum testosterone levels obtained in each
experimental group. For all the treated samples, the time points and dose levels
examined are before any overt histological change is apparent (Supplemental
Data S3); thus, the observed expression changes are due to transcriptional
regulation rather than changing cell numbers in the testis.
RNA Extraction
For each experimental sample, two biological replicates were obtained,
each replicate being itself a pool of two animals to ensure sufficient material for
hybridization. RNA from whole testis tissue was prepared using TRI reagent
(Sigma) according to the manufacturer’s protocol. Briefly, tissue samples were
homogenized in TRI reagent, followed by chloroform extraction. The aqueous
supernatant containing the RNA was retained, and the RNA precipitated with
isopropanol. RNA pellets were washed with 70% ethanol, air dried, and
resuspended in RNase-free water (Milli-Q). RNA concentration and integrity
was assayed with a Nanodrop 1000 spectrophotometer and an Agilent 2100
Bioanalyzer.
Microarray Hybridization and Scanning
Array profiling was performed using the MouseWG-6 v2.0 oligonucleotide
platform (Illumina). This comprises 45 281 probes from 30 789 different genes
and splice variants, essentially covering the whole murine transcriptome. Probe








labeling, hybridization, washing, and scanning were performed according to the
manufacturer’s protocols using the Illumina Total Prep kit (Applied
Biosystems). Briefly, first-strand cDNA was synthesized in a total volume of
20 ll with the supplied reagents. The complete first-strand product was used for
second-strand synthesis, followed by column purification. The purified product
was then used for in vitro transcription using T7 polymerase. Biotin-16-dUTP
was incorporated during this step, resulting in a biotinylated cRNA probe
suitable for hybridization. Probe integrity was verified using the Nanodrop 100
and Agilent 2100, as was done for the initial RNA samples. Labeled cRNA (1.5
lg) was hybridized to the array overnight at 588C in a total volume of 30 ll of
the manufacturer’s hybridization buffer, followed by posthybridization
stringency washing and scanning using Illumina standard protocols.
Data Analysis
Scanned array expression data were imported into BeadStudio (Illumina)
for normalization, preliminary analysis, and filtering. Quantile normalization
without background subtraction was used, and the Illumina custom error model
was used to generate present/absent calls for each probe (present is defined as P
, 0.01 for signal detection) on each array and to call differentially expressed
genes at each of the developmental stages (defined as P , 0.05 after false
discovery rate correction). Two samples with low labeling efficiency and weak
signal from housekeeping genes were judged as failed hybridizations and
excluded from further analysis. This affected one replicate from the 24-h
testosterone-treated time point and one replicate from the 27-h LuRKO
developmental sample. Normalized data from BeadStudio was filtered to
exclude genes not expressed in testis (i.e., data from probes that were classed as
absent in all samples). This yielded a final data set covering 30 389 probes from
21 305 different genes. ANOVA analysis and figure generation were
subsequently carried out using InforSense Discovery Edition (InforSense).
The full array data set has been submitted to GEO, accession number
GSE19453. Selected gene lists were used for gene ontology analysis using
GOEAST (gene ontology enrichment analysis) and KEGG (Kyoto encyclope-
dia of genes and genomes) pathways using Pathway-Express. Array results for
selected genes and samples were confirmed using quantitative RT-PCR
(Supplemental Data S4; supplementary methods available as Supplemental
Data S5).
RESULTS
LH Insensitivity Has Transcriptional Consequences
Throughout Prepubertal Testis Development,
Affecting over 10% of the Testis Transcriptome
Hierarchical clustering of the LuRKO and normal time
course samples according to the similarity of their global
expression profiles resulted in a tree (Fig. 1) that was in good
agreement with known histological data. That is, the Day 27
LuRKO samples clustered together with the Day 19 LuRKO
samples rather than with the Day 27 normal samples, indicative
of spermatogenic arrest at this stage. Significantly, however,
the analysis also revealed differences between LuRKO and
normal testes at Days 3, 8, and 13, with the knockout samples
being more similar to each other than to the age-matched
control samples. This signified that LH insensitivity had
consistent effects on the testis transcriptome at all ages, even
before hypoandrogenism set in.
In a paired t-test comparing the transcriptional profiles of
the complete LuRKO and normal time courses, 2738 probes
(2508 genes) were significantly up- or down-regulated with a
5% false discovery rate (FDR), and 833 probes (787 genes) of
these were significant when a 1% FDR was used (see
Supplemental Data S6). No fold change cutoff was used in
this comparison, allowing even subtle changes to be detected
so long as the changes were consistent throughout the time
course. Analysis of the down-regulated genes using Pathway-
Express [20] did not detect any known KEGG pathways [21] as
significant (see Supplemental Data S7). In contrast, several
KEGG pathways were found to be significantly overrepresent-
ed in the up-regulated genes. These pathways included axon
guidance, focal adhesion, Wnt signaling, and ECM (extracel-
lular matrix)-receptor interaction. Gene ontology analysis using
GOEAST [22] also failed to detect significant patterns among
the down-regulated genes (see Supplemental Data S7). Among
the up-regulated genes, gene ontology terms for transcription
and protein phosphorylation were significantly overrepresented
as well as related parent nodes in the gene ontology tree.
The Effects of LH Insensitivity on Somatic
and Germ Cell Transcriptomes Are Biphasic
Since testicular cell composition varies widely throughout
development, it is likely that there are many genes that are only
regulated by LH within a given developmental window and are
unchanged at other stages. Table 1 gives the number of genes
found to be significantly up- and down-regulated at each
individual time point postpartum. There proved to be a biphasic
distribution in the numbers of genes deregulated at each time
point. Days 3, 19, and 27 displayed the highest numbers of
changes, with fewer changes being apparent at Days 8 and 13.
This indicated that there were two successive waves of
transcriptional response to LH deficiency. The switch between
the two response phases occurred around Day 8 in our
experiment, concurrent with the appearance of adult Leydig
cells in the control testes.
In order to identify which cellular compartment was
predominantly affected in each wave of transcriptional
regulation, we compared the expression data for LuRKO
versus normal testes to data from testes of XXSxrb mice
(Supplemental Data S8). XXSxrb mice bear a translocation on
the X chromosome, which leads to sex reversal, the resulting
males being germ cell deficient and sterile. Germ cell genes are
underexpressed in XXSxrb testes, while somatic cell genes are
relatively overexpressed, thus allowing any given transcript to
FIG. 1. Hierarchical cluster analysis of the complete expression profile
for the LuRKO and normal developmental series. Biological replicates A
and B for each time point have been grouped together in pairs, and
LuRKO sample pairs have subsequently been grouped with the age-
matched control pairs in most cases. The sole exception is the Day 27
LuRKO sample, which groups together with the Day 19 LuRKO samples,
demonstrating the arrested testicular development at this age in LuRKO
males.








be presumptively assigned as being of germ cell or somatic cell
origin. Use of the mutant model is especially useful in that it
allows an independent assessment of somatic and germ cell
origin for any given transcript, in addition to the data obtained
from developmental profiling. We found that approximately
one-third of the probes altered in LuRKO testes could be
assigned to the germ cell or somatic cell compartments, with
the remainder either giving a mixed profile in the XXSxrb
comparison or not being present in the MEEBO oligonucle-
otide set (http://www.microarray.org/sfgf/meebo.do) used for
the XXSxrb profiling experiment. The final column in Table 1
summarizes the number of array elements found to be altered at
each time point and their likely cellular origin. At early ages
(Days 3–13), the regulated genes were preferentially identified
as somatic cell genes irrespective of the direction of the
regulation. At later ages (Days 19 and 27), a clear split became
apparent. Genes that were underexpressed in LuRKO testes,
and thus dependent on LH/testosterone activity, were predom-
inantly identified as germ cell genes. Conversely, genes that
were expressed at higher levels in LuRKO testes were
predominantly identified as somatic cell genes. This is likely
to be due to dilution effects, as a failure to activate germ cell
transcription means that somatic transcripts form a larger
proportion of total RNA in LuRKO testes and germ cell
transcripts a lower proportion. We note that at Day 19 there
was no clear histological difference between LuRKO and
normal testes; thus, for this time point, the dilution may be the
result of lower transcriptional activity per spermatid. At Day
27, there was a marked deficit in later stage spermatids in
LuRKO testes, and the observed changes were therefore likely
to be a result of the changing testicular composition.
Genes Affected by LH Insensitivity at Varying
Ages Postpartum Show Differential Responses
to Testosterone Treatment
For each of the sets of genes identified as up- or down-
regulated at each age, we examined the log
2
expression ratio in
RNA prepared from the maximally testosterone-treated animals
(2.5 mg of testosterone for 48 h) relative to untreated controls
in order to identify whether the genes concerned were
androgen responsive. Figure 2 shows box and whisker plots
indicating the net response of each group of genes to
testosterone treatment. For Days 13–27, genes identified as
down-regulated in LuRKO are on average induced by
testosterone treatment, while genes identified as up-regulated
in LuRKO are on average repressed by testosterone treatment.
No such pattern was apparent at Days 3 and 8, although genes
that were down-regulated in LuRKO testes at Day 3
surprisingly showed a down-regulation in response to testos-
terone treatment at Day 19.




testis relative to normal
Total no. of probes
(genes) regulateda
Proportion assigned to somatic/germ
cells in XXSxrb data setb
Day 3 DOWN 899 (874) 28%/11%
UP 170 (162) 22%/8%
Day 8 DOWN 43 (39) 23%/5%
UP 38 (36) 24%/11%
Day 13 DOWN 204 (191) 34%/8%
UP 139 (128) 14%/11%
Day 19 DOWN 1295 (1141) 8%/42%
UP 826 (755) 24%/4%
Day 27 DOWN 4643 (3849) 3%/37%
UP 6563 (5396) 28%/3%
a Numbers not in parenthesis indicate the number of individual oligonucleotide probes, while numbers in
parenthesis indicate the number of separate transcripts (which is slightly lower due to redundant representation
within the gene-set).
b Percentages indicate the proportion of probes which could be clearly assigned to somatic or germ cell
compartments by comparison to data from XXSxrb testes.
FIG. 2. Box and whisker plots indicating
the response to testosterone treatment for
the genes found to be up- or down-
regulated in LuRKO testes at each devel-
opmental stage. X axis: various groups of
developmentally regulated genes; y axis:
log
2
expression ratio of the 48-h treated
sample relative to untreated control. Dark
square indicates the mean, boxed area
indicates 50% limit, and whisker indicates
95% limit of the expression ratio for each
category.








First-Phase Effects of LH Insensitivity Affect Cell Adhesion,
Cytoskeletal Organization, and Protein Turnover
We used Pathway-Express to analyze the genes deregulated
at Day 3 in order to search for downstream pathways
potentially affected in fetal Leydig cells. In addition to the
WNT/focal adhesion pathway up-regulation, which was a
general feature at all ages (see above), there was up-regulation
of the KEGG pathways for the regulation of the actin
cytoskeleton, leukocyte transendothelial migration, and adhe-
rens junction function. Down-regulated pathways were ubiq-
uitin-mediated proteolysis, proteasome function, and basal
transcription factors.
Consistent with the pathway analysis, gene ontology
analysis of down-regulated genes showed an enrichment for
ontology terms related to protein folding, ubiquitination, the
mitochondrial electron transport chain, and the mitochondrial
ribosome large subunit, while up-regulated genes showed an
enrichment for ontology terms related to the actin cytoskeleton
and histidine catabolism. Significantly, steroid synthesis was
not identified as significantly changed by either the pathway
analysis or the gene ontology analysis, while known androgen-
responsive genes (see below) showed no change in expression
between LuRKO and normal testes at this age. This, therefore,
confirms the prior finding that androgen production by fetal
Leydig cells is not LH dependent and there is therefore no
disturbance of androgen pathway activity in fetal and early
neonatal LuRKO testes.
Surprisingly, Day 3 LuRKO testes also showed down-
regulation of several genes relating to synaptonemal complex
formation, namely Sycp1, Sycp2, Syce, and Rad51. The protein
products of these genes play a key role in meiosis. Their
mRNAs are expressed in spermatogonia, with transcript levels
peaking around Day 10 of postnatal life. At Day 3 postpartum,
very few spermatogonia are present in the testis, and most germ
cells are in the gonocyte stage. Absolute expression levels for
all four genes were very low in both genotypes at Day 3, and
thus the difference between LuRKO and normal at this age
may therefore represent random noise or may represent a delay
in differentiation of the first few spermatogonia in LuRKO
testes.
At Day 8, comparatively few genes were regulated in either
direction, and pathway analysis did not indicate any KEGG
pathways to be significant. While the WNT/focal adhesion
pathway did show up-regulation at Day 8, this was not
significant. GOEAST analysis of the down-regulated genes,
however, showed an enrichment for ontology terms related to
C21 steroid synthesis, particularly steroid hydroxylase activity.
This is consistent with the results of the previous candidate
gene studies (see also below). Ontology analysis of the up-
regulated genes indicated enrichment for rRNA transcription,
ribosome biogenesis, and DNA-dependent transcription. The
ontology term for steroid dehydrogenase activity was signif-
icant among the up-regulated genes, which proved to be due to
the significant up-regulation of Hsd11b1 and Hsd17b3 (exon 8
probe) at this time point. Up-regulation of Hsd17b3 was
observed by Zhang et al. [19] at Day 10 using primers that
detect exon 8, suggesting this is a genuine biological result,
although it was not statistically significant in their study.
Second-Phase Effects of LH Insensitivity Can Be Further
Subdivided into Early, Medium, and Late Categories
In order to analyze the second phase of LH-driven
transcriptional changes, we filtered the data set to select genes
found to be significant (P , 0.05 and 1.5-fold change) on at
least Day 8, 13, or 19, but which were unchanged (P . 0.05
and ,1.5-fold change) at Day 3. Day 27 was not included in
this comparison as most changes seen at Day 27 are due to
changes in the gross cellular composition of the testis rather
than changes in transcriptional activity of given genes. This
yielded an initial set of 2163 probes (1942 genes). These up-
and down-regulated genes were then subcategorized as early/
mid/late regulated, depending on whether they showed a
change on all three days (early), on Days 13 and 19 only
(middle), or on Day 19 only (late), giving six categories in
total. In all, 1965 probes (1769 genes) fell into one of these six
categories (see Supplemental Data S9 for gene lists and heat
maps). The remainder showed more noisy mixed patterns of
regulation, being up-regulated at some ages and down-
regulated at others. These mixed patterns were not analyzed
further. Table 2 shows summary data for the number of probes
falling into each category.
Early Second-Phase Effects Include Known Sertoli Cell
Androgen-Responsive Genes, while Late Second-Phase
Effects Herald the Onset of Spermatogenic Arrest
Very few of the second-phase transcriptional changes were
detected at Day 8, with only 10 genes falling into the early
category. Eight of these were down-regulated in LuRKO
(Defb45, Drd4, Insl3, Kcnk3, Lmcd1, Pla1a, Rhox5, and
Spinlw1), and two were up-regulated (Npm3 and Rock2).
Importantly, of these, Drd4, Rhox5, and Spinlw1 are known to
be androgen-responsive Sertoli cell genes [23]. This strongly
suggests that hypoandrogenism in LuRKO testes sets in as
early as Day 8, concurrent with the first appearance of adult-
type Leydig cells in the control testes. Pathway analysis and
TABLE 2. Genes from the second phase of responses to LH insensitivity, defined as a significant change at Day 8,
Day 13, or Day 19 and no significant change at Day 3.
Categorya
No. of probes (genes)
changed between
LuRKO and normalb
No. of probes (genes)
also regulated in
timecourse datab
No. of probes (genes) showing
dose-dependent regulationb
Early DOWN 10 (8) 8 (6) 8 (6)
UP 2 (2) 1 (1) 0 (0)
Middle DOWN 79 (76) 66 (65) 26 (26)
UP 44 (41) 24 (21) 4 (4)
Late DOWN 1139 (1011) 932 (836) 53 (51)
UP 691 (648) 565 (529) 55 (52)
a Categories were defined as early (change seen at Days 8, 13, and 19), middle (change seen at Days 13 and 19, not
Day 8), or late (change seen at Day 19 only) (see Results) and were followed by ANOVA testing to determine
whether they were induced during the testosterone treatment timecourse and/or the dose-response series.
b Numbers not in parenthesis indicate the number of individual oligonucleotide probes in each category; numbers
in parenthesis indicate the number of separate transcripts.








gene ontology analysis was not possible owing to the small
number of genes in the early category. In the middle second-
phase category, once again the number of regulated genes was
too low for conclusive gene ontology results.
GOEAST analysis of down-regulated transcripts in the late
second-phase category showed highly significant enrichment
for multiple terms related to germ cell development and
function, including the ontologies for sexual reproduction,
spermatogenesis, male gamete generation, spermatid develop-
ment, flagellum, outer dense fiber, acrosomal vesicle, acroso-
mal membrane, sperm motility, sperm-egg recognition, and
fertilization. Despite this, no known KEGG pathways were
found to be significant in the late-phase gene list, indicating the
very poor state of knowledge concerning the genetic pathways
underlying spermatid maturation. Once again, components of
the WNT pathway related to tight junctions and focal adhesion
were significant among the genes up-regulated in LuRKO;
however, in this case the up-regulated genes appeared to relate
to the tight junction pathway rather than the focal adhesion
pathway seen up-regulated at earlier ages, including Day 3. The
late second-phase category included several further genes
previously identified as Sertoli cell androgen response genes,
specifically Gpd1, Serpina5, Tpd52l1, and Tsx [23]. These may
be downstream or secondary responses occurring after the
upstream responses in the early category.
Testosterone Treatment in LuRKO Reinitiates the Normal
Prepubertal Transcriptional Program
Our initial analysis (see above) indicated that the second-
phase genes were testosterone responsive. We therefore
performed a close analysis of the time course response of
these second-phase genes to treatment with 2.5 mg testoster-
one. First, we filtered the second-phase gene list for each
category to select for probes showing significant changes in
expression across the testosterone treatment time course
(ANOVA P , 0.05 after FDR correction) and where the
direction of change was consistent between the developmental
series and the treatment time course, that is, a down-regulation
in LuRKO being corrected by testosterone administration or
vice versa. The large majority (1596 of 1965) of oligonucle-
otide probes matching second-phase genes passed this filter,
indicating that most of the second-phase responses to LH
insensitivity were corrected to some extent by testosterone
treatment. Table 2 shows the breakdown of these genes
according to our early/mid/late categorization, and Figure 3
shows box and whisker plots for the testosterone-responsive
genes in each of the categories.
Early genes, where there is a difference between LuRKO
and normal from Day 8 onward, responded to testosterone
within 12 h of treatment, while middle and late genes, where
there is no difference between LuRKO and normal until Days
13 and 19, only responded to testosterone after 48 h of
treatment if at all. Thus, the temporal sequence of gene changes
in response to testosterone rescue of the LuRKO phenotype
mirrored the events seen in normal prepubertal development.
Dose-Dependency of Early Testosterone-Responsive Genes
We wished to establish whether any of our candidate
testosterone-responsive genes showed a dose-dependent re-
sponse to testosterone stimulation. We therefore filtered the list
of second-phase genes to select for probes showing significant
change in expression across the dose response sample series
time course (ANOVA P , 0.05 after FDR correction) and
where the direction of change was consistent with the existing
data. Table 2 indicates the number of genes in each category
that passed this final filter. Most of the genes in the middle and
late categories did not show any significant dose sensitivity.
This is almost certainly due to the fact that most of these genes
only change in expression after 48 h of testosterone
stimulation, and the dose response sample series was taken at
24 h after the treatment. However, all of the remaining six
genes in the early down-regulated category passed this filter.
These genes—Defb45, Drd4, Lmcd1, Pla1a, Rhox5, and
Spinlw1—were activated in the normal testis relative to
LuRKO from Day 8 onward, they responded to androgen
treatment within 12 h, and they were sensitive to low dosages
of androgen. They are thus key candidates for a regulatory role
in the androgen-dependent progression of spermatogenesis. It
is interesting to note that these changes occurred well before
the spermatogenic block became evident. This suggests that
these genes have an upstream role in preparing the somatic cell
compartment to support the subsequent germ cell development.
Known Leydig Cell Genes: Developmental Profile
and Testosterone Sensitivity
Finally, we examined the expression of the known Leydig
cell genes identified by O’Shaughnessy et al. [17]. Table 3
shows the log
2
ratio expression data in LuRKO mice relative to
control testes across the time course and the log
2
expression
ratio for the sample from the maximally treated animals (2.5
mg of testosterone for 48 h) relative to the untreated control. Of
the genes they identified, the Lhcgr data is not shown here
because the expression is negligible at all ages in LuRKO.
Estrogen sulfotransferase (Sult1e1) was not present in our data
set. Multiple measurements for the same gene indicated the
presence of multiple probes on the array. In the case of
Hsd17b3, probes directed at different exons showed differing
expression patterns, potentially indicating differential regula-
tion splice variants for this transcript.
Of these known Leydig cell genes, Cyp11a1, Cyp17a1, and
Hsd3b1 were down-regulated at Day 3, indicating LH-
dependence in fetal Leydig cells. Insl3, Star, and Srd5a1 also
showed moderate down-regulation at early ages, although they
were not significant. The above six genes were all significantly
down-regulated at later ages, indicating LH-dependence in
adult-type Leydig cells. Ephx1 appeared to be LH dependent in
adult but not in fetal Leydig cells, while Vcam1 was specific to
adult cells and was LH dependent. Akr1c14 was down-
regulated at Day 3 but not at later ages. The fetal cell-specific
marker Thbs2 showed progressive up-regulation throughout the
first wave in LuRKO relative to control, demonstrating the late
retention of fetal-type Leydig cells in LuRKO testes. Gstm2
showed this pattern also. These results are broadly in
agreement with those of Zhang et al. [19] except that their
study did not detect the early down-regulation of Cyp11a1,
Cyp17a1, and Hsd3b1. It is likely that the semiquantitative RT-
PCR technique they used is less sensitive than the array method
used here. It may be significant that their RT-PCR results for
Hsd17b3 are consistent with our results for exon 8 of this gene
because their study used a forward primer in exon 1 and a
reverse primer at the exon 7/8 border, thus, selectively
detecting transcripts containing these exons.
When we examined the testosterone sensitivity of the
known Leydig cell genes, the results were mostly as expected.
Those genes that were down-regulated in LuRKO were
induced by testosterone treatment and vice versa, although
this was not always statistically significant at 48 h. Insl3
showed little response to testosterone, indicating that its
expression was directly dependent on LH and not on androgen








activity. The same was true of Srd5a1. Star showed only a
moderate nonsignificant reduction in expression at early ages
with no difference between normal/LuRKO/treated LuRKO at
Day 19, indicating that expression of this gene may be
independent of the LH/androgen pathway in neonatal and
juvenile testes. This is consistent with reports that the
antiandrogen flutamide did not affect Star expression in
neonatal rat testes [24]. The fetal Leydig cell marker Thbs2
was down-regulated by testosterone, despite the fact that its
expression was not LH sensitive.
DISCUSSION
Microarray analysis of spermatogenesis is a rapidly
developing field. Array analysis has been used to analyze
various stages of germ cell development in mouse and human
to look for transcriptional consequences of given infertility
phenotypes, to identify disease genes affecting testis function,
and to identify regulatory interactions at the single gene and
whole chromosome level [25–35]. A number of microarray
studies have attempted to identify androgen targets within the
testis; however, there is considerable variation in the published
findings that likely reflects the different mutants used, different
background strains on which the mutations are maintained,
different ages analyzed, and various array platforms. A
particular difficulty in the field is the interpretation of data
from later stages of testicular development where there are
marked differences in cellular composition between the mutant
and control samples. For example, in the Tfm mouse, where
there is inactivation of the androgen receptor throughout the
testis, O’Shaughnessy et al. [36] identified 20 genes of somatic
tubular origin as significantly down-regulated at Day 20
postnatal and 6 genes as up-regulated, suggesting that the
FIG. 3. Box and whisker plots indicating the response to testosterone treatment for the various subcategories of testosterone-responsive genes. A) Early
down-regulated genes, (B) early up-regulated genes, (C) middle down-regulated genes, (D) middle up-regulated genes, (E) late down-regulated genes, and
(F) late up-regulated genes. Early, medium, and late categories are defined in the Results and shown in Table 2. X and y axes, boxes, and whiskers are as in
Figure 2. Panel B contains only a single probe, and thus there are no boxes for this panel. Developmental time course data and testosterone treatment time
course data are shown for all six categories. Panel A additionally shows the dose-response data for early down-regulated genes because this category was
responsive to low-dose testosterone.








predominant action of testosterone is to activate gene
transcription. In contrast, Eacker et al. [37] compared an
androgen receptor hypomorph, in which receptor action is
reduced in cells throughout the testis, to the same model with
an additional Sertoli cell-specific deletion of the androgen
receptor. This group found the opposite pattern, with more
genes showing up-regulation than down-regulation and
consequently concluded that testosterone has a predominantly
repressive action in the adult testis. It is, however, likely that
these conclusions are affected by the methodology used in the
two studies. In both cases, at the age used for the study,
spermatogenic arrest has already set in, and there is a
significant increase in somatic cell proportion in the testis.
O’Shaughnessy et al. [36] corrected for this by applying a more
stringent fold-change filter to up-regulated than to down-
regulated genes, consequently detecting comparatively few up-
regulated genes. Eacker et al. [37] did not apply such a
correction, therefore, preferentially detecting up-regulated
genes and being less sensitive to down-regulated genes.
In the work presented here, we avoid this difficulty by using
age-matched controls for the developmental time course
analysis and by focusing on the early responses to LH
insensitivity and testosterone rescue before there are gross
changes in testicular histology. Our results are in good
agreement with other studies using a similar methodology,
for example, Denolet et al. [23], who examined SCARKO
testes at Day 10 postnatal, prior to spermatogenic arrest. This
group identified nine genes that were strongly down-regulated
in SCARKO mice relative to control littermates and that were
also repressed by the antiandrogen flutamide. Of these nine
genes, namely, Rhox5, Spinlw1, Galgt1, Drd4, Tsx, Gpd1,
Tubb3, Serpina5, and Tpd52l1, all except Galgt1 and Tubb3
were found to be androgen responsive in our study. Our study
extends their results by separating androgen effects into early
and late responses (see below), thus, giving further information
about the regulation of Sertoli cell function by testosterone.
Interestingly, several of these genes were also found to be
regulated by FSH in the hpg mouse [38], suggesting that
Sertoli cells potentiate Leydig cell function when stimulated by
FSH. This latter study also used an experimental design
focused on the early transcriptional responses to treatment,
avoiding the confounding effect of changes in testicular
composition. We believe this to be critically important to the
correct interpretation of future studies in this field.
Our study is the most systematic investigation of in vivo
testicular androgen responses to date. The key finding is that
there is a biphasic response to LH insensitivity, that is, a first
transient phase at Day 3 that is largely self-correcting by Day 8
and a more sustained second phase with onset from Day 8
onward. The next question is which of the changes seen in
LuRKO are direct effects of LH insensitivity and which are due
to reduced androgen secretion. For the first-phase genes,
although we observed down-regulation of Cyp11a1 and
Cyp17a1 at Days 3 and 8 in LuRKO relative to control, these
being the rate-limiting enzymes for steroid synthesis, the
majority of genes changing at these ages did not appear to be
testosterone responsive. The first phase thus appears to be
predominantly an androgen-independent response to the lack of
LH stimulation. A significant caveat here is that the
testosterone response was measured in Day 19 testes. To
formally establish whether the first-phase genes in Day 3 testes
are testosterone responsive would require experimental (and
unphysiological) treatment of neonatal animals with testoster-
one. It is however anticipated that perinatal transcriptional
changes in LuRKO should be androgen independent because
the normal masculinization of LuRKO male internal genitalia
indicates that fetal androgen activity is unaffected by the
receptor knockout [5]. Androgen secretion by fetal Leydig cells
is thus presumed not to depend on LH, or at least to be
redundantly controlled by other factors [38]. Fetal Leydig cells
are responsive to LH in culture [12]; however, the physiolog-
ical import of this is unclear. Direct measurements of perinatal
testosterone in LuRKO are contradictory, with Zhang et al. [19]
finding no change in testosterone at birth and Abel et al. [38]
TABLE 3. Log
2
ratio expression data for the known Leydig cell genes identified by O’Shaughnessy et al. [17] and grouped according to the expression
patterns observed.
Group Expected expression pattern [17] Gene
LuRKO versus control during developmenta
48-h treated versus
untreated at Day 19aDay 3 Day 8 Day 13 Day 19 Day 27
1 Fetal/adult Leydig cells, induced
and sustained at puberty
Cyp11a1 0.73 1.07 1.04 1.40 0.99 0.34
1 Cyp17a1 1.79 2.29 1.89 3.71 4.21 1.61
1 Ephx1 0.01 0.00 0.48 0.56 1.09 0.35
1 Gstm2 0.14 0.04 0.04 0.41 0.70 0.23
1 Gstm2 0.08 0.21 0.01 0.56 0.89 0.29
1 Gstm2 0.08 0.01 0.06 0.44 0.35 0.16
1 Insl3 0.24 1.38 2.15 2.64 2.90 0.14
1 Insl3 0.62 1.40 2.35 3.55 2.88 0.15
1 Star 0.28 0.41 0.24 0.05 0.01 0.00
2 Specific to adult Leydig cells Hsd17b3 (exon 4) 0.34 0.10 0.01 0.13 0.33 0.07
2 Hsd17b3 (exon 8) 0.50 0.67 0.17 0.39 0.23 0.57
2 Hsd17b3 (exon 9) 0.59 0.28 0.19 0.09 0.12 0.38
2 Hsd3b6 0.02 0.11 0.20 0.17 0.46 0.14
2 Ptgds 0.25 0.06 0.25 0.31 0.40 0.42
2 Vcam1 0.14 0.09 0.47 0.84 0.46 0.75
2 Vcam1 0.07 0.23 0.48 0.83 0.70 0.21
3 Specific to fetal Leydig cells Thbs2 0.32 0.34 0.50 0.91 0.60 0.91
4 Fetal/adult Leydig cells, peaking
at puberty and dropping thereafter
Akr1c14 1.04 0.04 0.12 0.01 0.73 0.24
4 Akr1c14 0.65 0.12 0.22 0.18 0.34 0.04
4 Srd5a1 0.28 0.35 0.37 0.72 0.73 0.09
5 Low level in fetal/adult Leydig cells,
no pubertal induction
Abcc9 0.36 0.07 0.01 0.09 0.16 0.24
5 Abcc9 0.12 0.01 0.11 0.10 0.02 0.41
5 Hsd3b1 1.58 0.48 0.53 0.65 0.79 0.79
a Boldface text indicates significant down-regulation; boldface and italics indicate significant up-regulation.








finding a marked reduction. A final factor to consider here is
that the androgen receptor is not immunologically detectable
on Sertoli cells until Day 5 of postnatal development [39], and
thus even if perinatal testosterone production is affected in
LuRKO, this may not have any consequence in the testis.
Overall, our results in Day 3 testis should be taken as
supporting the findings of those of Zhang et al. [19] and
indicative of no major changes in androgen pathway activity in
neonatal LuRKO males.
In contrast, the second phase of responses to LH
insensitivity is largely testosterone dependent in that replace-
ment therapy acts to correct the transcriptional changes seen in
LuRKO males. The majority of second-phase changes only set
in at postnatal Day 13 or Day 19; however, six genes (see
below) show an androgen-dependent change as early as Day 8.
This stands in stark contrast to measurements of testicular and
serum testosterone levels, which show low (and decreasing)
androgen levels at this age [38]. It is, however, consistent with
the down-regulation of androgen synthesis genes seen at this
age by us and others [19], and with the growing body of results
from the SCARKO model, indicating that there are some
androgen-dependent changes in gene expression as early as
postnatal Day 4 [39]. Strikingly, we found that these early
genes were induced within 8–12 h of testosterone administra-
tion, with Rhox5 and Drd4 showing even earlier induction
within 2–4 h of treatment. Early genes were also induced by
lower doses of testosterone, showing almost full induction at
25 lg and some induction with as little 2.5 lg; this is 100-
1000-fold lower than the dosage required to mimic pubertal
testosterone levels. Serum testosterone measurements for the
dose-response experiment surprisingly showed little difference
between the doses at the low end of the range analyzed in our
study (see Supplemental Data S2) despite the fact that
significant transcriptional changes were seen between, for
example, the 2.5 and 25 lg samples. It may be that serum
levels do not directly reflect intratesticular levels of testoster-
one. Further experimentation will be required to pinpoint the
critical range of intratesticular androgen levels required to
activate the spermatogenic program. Nevertheless, taken
together, our data indicate that there are indeed early acting
androgen effects during prepubertal testis development medi-
ated by basal levels of testosterone.
Efforts to date at identifying key androgen response genes
have focused largely on the Sertoli cell because of the
availability of a selective receptor knockout model. Subsequent
use of the same Cre/lox technology has generated models with
a meiotic/postmeiotic germ cell androgen receptor knockout
[40], a peritubular myoid cell androgen receptor knockout [11],
and a Leydig cell androgen receptor knockout [12]. Our
analysis is complementary to and extends these other studies in
that the time course analysis can separate early androgen
responses from later responses. For example, of the Sertoli cell
androgen responsive genes identified by Denolet et al. [23],
Drd4, Rhox5, and Spinlw1 were early second-phase genes in
our analysis, while Gpd1, Serpina5, Tpd52l1, and Tsx fell into
the late second-phase category. Moreover, our analysis is not
restricted by cell type and will detect androgen response genes
irrespective of their site of expression. Defb45, Lmcd1, and
Pla1a may well be responding in cell types other than Sertoli
cells because they were not identified in the Denolet et al.
SCARKO study [23].
The six genes we identified as showing an early change
between LuRKO and control, an early response to testosterone
treatment, and a response to low-dose testosterone are Defb45,
Drd4, Lmcd1, Pla1a, Rhox5, and Spinlw1. Three of these—
Drd4, Rhox5, and Spinlw1—have previously been identified as
androgen-responsive Sertoli cell genes, while the other three
are here identified for the first time as putative androgen
targets. Of these genes, Rhox5 is the best categorized. It is a
reproductive homeobox gene with two promoters, the proximal
promoter being Sertoli cell-specific and androgen responsive
[41]. It has four androgen response elements in the proximal
promoter, and members of the GATA family of transcription
factors are also necessary for successful transcription of Rhox5
[42]. In this light, it is interesting that another of the six genes
in question, Lmcd1, is a transcriptional cofactor repressing the
activity of GATA6 [43]. It may thus be playing a role in
moderating Rhox5 expression or in restricting expression of
Rhox5 to Sertoli cells by repressing GATA6 activity in other
cell types. Spinlw1 (eppin) and Drd4 (dopamine receptor 4) are
androgen regulated in SCARKO testes [23]. Nothing is known
about the function of either during testis development, although
Spinlw1 is also an epididymal protein that coats mature sperm
and has been investigated for a potential role in contraceptive
vaccination [44]. Defb45 has been identified by automatic
genome annotation as a member of the defensin family of
antimicrobial peptides. Nothing is yet known about its role in
the testis. Pla1a is a phosphatidylserine-specific phospholipase
that hydrolyzes cell surface lipids to generate lysophosphatidic
acid [45], which in turn is a paracrine signal promoting germ
cell survival [46].
What then governs the onset of hypoandrogenism in
LuRKO males? Does it relate to the appearance of the
androgen receptor on Sertoli cells (Day 5 onward) or to the
appearance of adult-type Leydig cells in the testis (Day 7
onward)? While our current data set does not address this
directly, evidence from older LuRKO mice suggests that the
critical factor is Leydig cell maturation. Old (12 mo) LuRKO
males show breakthrough spermatogenesis, with every type of
germ cells being present in the testis even though testosterone
levels are still at basal levels (2% of controls). This
spermatogenic breakthrough is abolished by treatment with
the antiandrogen flutamide, indicating that the breakthrough is
androgen dependent. Twelve-month-old LuRKO males remain
cryptorchid, and accessory organs such as the epididymis,
seminal vesicles, and external genitalia do not develop,
indicating that the LH-driven pubertal testosterone surge is
necessary for these structures, though not for spermatogenesis
itself. Crucially, these aging males with breakthrough sper-
matogenesis also have adult-type Leydig cells [18]. This has
two key implications: firstly, that adult Leydig cells (but not
fetal cells) secrete a basal level of testosterone that is sufficient
to reinitiate and support spermatogenesis, and secondly, that
this basal level of testosterone production is independent of
LH. In our data set, we see an overexpression of the fetal
Leydig cell gene Thbs2 from Day 8 onward, corresponding to
the retention of fetal-type cells. We also see an underexpression
of several of the group 1 (adult Leydig cell specific) genes
identified by O’Shaughnessy et al. [17]. Taken together, it
appears that the critical factor behind the androgen-dependent
spermatogenic delay in LuRKO is a failure to develop adult-
type Leydig cells at the normal age.
So what drives Leydig cell maturation? Our data set shows
that the fetal Leydig cell gene Thbs2 was down-regulated by
testosterone replacement therapy, suggesting that testosterone
treatment acts to reduce fetal Leydig cell activity. Conversely,
several genes specific to adult Leydig cell genes were induced
by testosterone in this experiment. Importantly, this included
Cyp17a1 itself, the rate-limiting enzyme for androgen
synthesis—a paradoxical result since this enzyme is well
documented to be repressed by testosterone in adult Leydig
cells via an autocrine feedback mechanism [12]. Our








interpretation of this is that testosterone treatment triggers
differentiation of adult-type Leydig cells, which are not present
at all in the untreated Day 19 LuRKO testis. The appearance of
these cells in the testis following treatment thus presents as an
up-regulation of Cyp17a1 despite the fact that testosterone acts
to repress Cyp17a1 on a per-cell basis. Alternatively, it may be
that Cyp17a1 is regulated differently by testosterone in fetal
and adult Leydig cells.
We therefore propose a model whereby the ability to
produce adult Leydig cells is dependent on androgen activity.
Once the first few adult Leydig cells have differentiated, they
secrete androgens favoring further differentiation, thereby
setting up a positive feedback switch leading to ongoing
maintenance of an adult Leydig cell population. The 12-mo
LuRKO phenotype shows that while LH stimulation is
necessary for the correct timing of the switch from fetal- to
adult-type cells during normal testis development and for
establishing normal Leydig cell numbers, it is not an absolute
necessity for adult Leydig cell differentiation. In aging LuRKO
animals, the switch may be tripped by other endocrine factors,
or it may even be entirely stochastic because in the suggested
model the replacement is self-reinforcing once initiated.
Testosterone levels in LuRKO at 7 wk were higher than in
castrated mice, indicating that the adult Leydig cell population
may have begun to appear by this point [5]. In support of our
model, adult Leydig cells fail to develop in Tfm mice lacking
androgen receptor function [47] but do develop in SCARKO
mice [48], in mice lacking the androgen receptor in Leydig
cells [12], and in mice lacking the androgen receptor in
peritubular myoid cells [11]. Also consistent with our proposal,
Hardy et al. [49] found that LH and androgens had a
synergistic effect on the differentiation of adult Leydig cells
from peritubular mesenchymal precursors in rat cell culture.
Figure 4 shows a schematic representation of this model
indicating androgen secretion by fetal and adult Leydig cells
and the point at which the SCARKO and LuRKO models
perturb the normal situation. Also included in this figure is the
absolute expression data for LuRKO and control males for the
fetal/adult Leydig cell antigens found to be testosterone
regulated in our study, illustrating the switch over from fetal-
to adult-type cells in controls and the failure of this process in
LuRKO males. Ephx1 and Cyp17a1 are expressed in both fetal
and adult cells. In control mice, there is a small drop in
transcript levels as fetal cells are replaced by quiescent adult
FIG. 4. Schematic representation of the
secretion of testosterone by fetal and adult
Leydig cells during gestation, postnatally,
and in the adult. The switch over from fetal-
to adult-type Leydig cells occurs prepuber-
tally, starting around Day 7. LuRKO males
are hypoandrogenic from this point forward
due to a failure to develop adult Leydig
cells. Lower panels show transcriptional
data for selected fetal/adult Leydig cell
antigens during the period. The dotted
arrows in these panels indicate the effect of
48 h of testosterone treatment at a dose of
2.5 mg.








cells (quiescent due to low LH levels at this age). In LuRKO,
there is a progressive reduction relative to control as the adult
cells fail to develop. Testosterone treatment allows adult cell
development and increases levels of these transcripts. Vcam1 is
expressed specifically in adult Leydig cells. It becomes
activated between Days 8 and 13 in control males but not in
LuRKO. Testosterone treatment of LuRKO males increases the
levels of this transcript. Thbs2 is expressed specifically in fetal
Leydig cells. It decreases markedly in control males throughout
development as fetal cells are replaced. In LuRKO, transcript
levels are a little higher due to the retention of fetal-type cells.
Testosterone treatment lowers the level of this transcript,
implying that testosterone represses fetal Leydig cell activity
and/or triggers their replacement by adult Leydig cells.
The model makes three key predictions, which we aim to
test in future experiments.
1. Low-dose testosterone therapy in LuRKO will allow
resumption of spermatogenesis without being sufficient to
trigger testicular descent and accessory gland development,
that is, it will mimic the 12-mo-old LuRKO phenotype.
2. Testosterone therapy will drive Leydig cell maturation in the
absence of LH; thus, in rescued LuRKO mice, the Leydig
cells should show an adult phenotype.
3. Once the adult Leydig cells are present in the testis, they will
be able to maintain the necessary basal testosterone level;
thus, in rescued LuRKO mice, spermatogenesis will
continue even if testosterone treatment is subsequently
stopped.
A final question to pose is what is the biochemical basis of
the delayed Leydig cell maturation in LuRKO? Clues to this
can be found by looking to the transcriptional changes found in
common between all the analyzed ages, in particular, the
changes seen at Day 3. In this regard, a clear conclusion from
the gene ontology pathway analysis is that genes affecting the
WNT pathway and cell adhesion are up-regulated in LuRKO;
however, the specific type of adhesion involved is age
dependent. Focal adhesion genes and matrix adhesion genes,
including integrins Itga6 and Itga11, collagens Col3a1 and
Col5a2, laminins Lama1 and Lamc1, vitronectin, fibronectin,
actinin Actn4, and beta actin, were up-regulated at all ages.
Tight junction genes, including key junction components
claudin Cldn1 and occludin Ocln, were only up-regulated
from Day 19 onward.
The later effect on tight junctions is likely to be a
downstream consequence of hypoandrogenism, although the
interpretation is complex because flutamide has been shown
to down-regulate tight junction components in rat testes [50],
contrary to the up-regulation seen here. Since the focal/matrix
adhesion effects are seen in the paired t-test analysis, which
examines all the days including Day 3, these appear to be
testosterone-independent effects of LH and may relate to the
correct maturation of Leydig cells. The origin of mature
Leydig cells is unclear in that they do not appear to
differentiate directly from fetal cells. Peritubular mesenchy-
mal cells and perivascular smooth muscle cells have both
been proposed as candidate stem cells for this population,
with the evidence largely favoring the former. These
mesenchymal cells are also the precursors for the peritubular
myoid cell lineage in the adult testis [51]. A fruitful avenue
for future study will be the influence of testosterone on the
precursor mesenchymal cells. Does testosterone affect the
decision of whether to become an adult Leydig cell or a
mature myoid cell? In particular, is it a necessary permissive
factor allowing differentiation of adult Leydig cells? What
junctional connections exist between peritubular mesenchy-
mal cells and other cell types, and do alterations in these
connections affect mesenchymal cell fate?
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